A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
Latest Information Update: 08 Aug 2023
At a glance
- Drugs Verzistobart (Primary)
- Indications Advanced breast cancer; Cancer; Colorectal cancer; Lung cancer
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 01 Aug 2023 According to a Incyte corporation media release, Discovery of INCAGN-2390 is in collaboration an Agenus.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 12 Nov 2021 Status changed from active, no longer recruiting to completed.